Bipolar Disorder: Market Research Report
This report analyzes the worldwide markets for Bipolar Disorder in US$ Million.
The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific and Rest of World.
Annual estimates and forecasts are provided for each region for the period 2006 through 2015.
The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co.Ltd., Eli Lilly and Company, Forest Laboratories, Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica, Inc., Parent Company Profile - Johnson and Johnson Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer, Inc., Repligen Corporation, and Validus Pharmaceuticals, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific and Rest of World.
Annual estimates and forecasts are provided for each region for the period 2006 through 2015.
The report profiles 53 companies including many key and niche players such as Abbott Laboratories, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co.Ltd., Eli Lilly and Company, Forest Laboratories, Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica, Inc., Parent Company Profile - Johnson and Johnson Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer, Inc., Repligen Corporation, and Validus Pharmaceuticals, Inc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Atypical anti-psychotics
Other Therapeutics
II. EXECUTIVE SUMMARY
1.GLOBAL MARKET OVERVIEW
Bipolar Disorder Facts
A Market with Unmet Medical Needs
A Major Burden on Society
Current and Future Analysis
Patent Expiries Depress Market Growth
Patent Expiries of Major Bipolar Disorder Drugs
Loss of Exclusivity to Continue
Poor Pipeline Dims Prospects for Market Growth
A Few Bright Spots
Opportunities and Challenges
The Clinicians’ Quest for The Best - Seroquel XR
Children and Teens – The Targets or the Beneficiaries!
Adverse Events - A Major Issue with Antipsychotics
Side Effects Influence Prescription Trends
2.COMPETITIVE LANDSCAPE
A Market Sans Competition
Bipolar Disorder Drugs Market (2009): Five Major Companies with Marketed Products
Antipsychotics – The Mainstay Therapy
Antidepressants
Antiepileptics – Prescriptions Continue Despite Warning
Select Antiepileptics with Approved Bipolar Disorder Indications
3.A REVIEW OF SELECT LEADING DRUGS
Abilify (Aripiprazole)
Geodon/Zeldox (Ziprasidone)
Invega (Paliperidone)
Lamictal (Lamotrigine)
Risperdal (Risperidone)
Risperdal® Consta® (Risperidone)
Saphris (Asenapine)
Seroquel (Quetiapine)
Seroquel XR
Zyprexa (Olanzapine)
Other Drugs
Depakine (Sodium Valproate)
Depakote/ Depakote ER (Divalproex Sodium)
Tegretol (Carbamazepine)
4.PIPELINE ANALYSIS
A Few Battle Big Challenges
Drug Development Pipeline for Select Bipolar Disorder Candidates
Bipolar Disorder Drugs (2009) –Select Companies with Products in Late Stage Clinical Development (Phase II, III, Pending Approvals)
A Review of Select Leading Pipeline Candidates
Lurasidone (SM-13,496)
Zomaril
Nuvigil (armodafinil)
RG2417 (Uridine)
RGH-188 (Cariprazine)
AZ - 004 (Staccato Loxapine)
Lu AA39959
Lu AA34893
5.DISEASE OVERVIEW
Introduction
History
Causes of Bipolar Disorder
Triggers
Episodes in a Bipolar Disorder
Classification of Bipolar Disorder
Bipolar Disorder Classification
Symptoms of Various Types of Bipolar Disorder
Mania
Hypomania
Mixed State
Depression
Additional Symptoms of Bipolar Episode
Treatment of Bipolar Disorder
Psychosocial Treatments
Hospitalization for Extreme Cases
6.CLINICAL TRIALS
Cephalon Announces Promising Phase II Clinical Results of NUVIGIL
Repligen Commences Phase IIB Trial of RG2417
Forest and Gedeon Richter Announce Favorable Phase II Results for Cariprazine
Alexza Commences Preliminary Phase 3 Trail with Staccato® Loxapine
Dainippon Sumitomo to Conduct Clinical Study for Lurasidone
7.PRODUCT APPROVALS AND LAUNCHES
AstraZeneca Introduces Seroquel XR® in North America
AstraZeneca Introduces Seroquel XR in Europe
Wockhardt to Roll Out Divalproex ER Tablets
FDA Approves SEROQUEL for Paediatric Treatment of Schizophrenia and Bipolar Disorder
FDA Approves Eli Lilly's Zyprexa for Schizophrenia and Bipolar Indications
Pfizer Canada Receives Approval from Health Canada for ZELDOX
Ortho-McNeil-Janssen Receives FDA Approval for RISPERDAL® CONSTA®
FDA Grants Approval to Eurand for EUR-1048
Merck/Schering-Plough Receives EMEA Approval for SYCREST®
FDA Approves SAPHRIS(R) for Treatment of Mixed/Manic Episodes of Bipolar Disorder and for Acute Treatment of Schizophrenia in Adults
FDA Grants Marketing Approval to Glenmark for Lithium Carbonate Capsules
Ranbaxy Australia Receives Approval from Therapeutic Goods Administration
Servier Obtains Approval for Valdoxan®/Thymanax®
Pfizer Canada Receives Approval from Health Canada for ZELDOX Drug
Pfizer Obtains Extended Approval for Geodon
FDA Considers Approval of Psychiatric Medications for Children
FDA Weighs Zyprexa for Two Juvenile Indications
Caraco Pharmaceutical Introduces Divalproex Sodium Delayed Release Tablets
BMS and Otsuka Obtain European Marketing Approval for ABILIFY® for Manic Episodes
ABILIFY® Obtains Extended Indications in Schizophrenia and Bipolar I Disorder
AstraZeneca Receives European MRP Approval for SEROQUEL and SEROQUEL XR
FDA Approves Seroquel XR® Extended Release Tablets
Mylan Pharmaceuticals Receives FDA Approval for Risperidone Tablets USP
Depakote Generic Drug Receives FDA Approval
Noven Pharmaceuticals Receives FDA Approval for Stavzor™
BMS and Otsuka Receive FDA Approval for ABILIFY®
Lupin Obtains FDA Approval for Divalproex Sodium Delayed-Release Tablets
Orchid Chemicals Obtains FDA Approval for Divalproex Sodium Delayed
Noven Pharmaceuticals Receives FDA Approval for Stavzor Capsules
Sun Pharmaceutical Industries Receives USFDA Approval for Depakote Divalproex Sodium Tablets
8.RECENT INDUSTRY ACTIVITY
Abbott Takes Over Solvay Pharmaceuticals
Merck & Co. Merges with Schering-Plough
Pfizer Acquires Wyeth
Hisamitsu Pharmaceutical and Hisamitsu U.S. Take Over Noven Pharmaceuticals
Avacta Group Acquires TheraGenetics
BMS and Otsuka Extend their Agreement on Ability
ADA Technologies to Develop Home Lithium-Monitor for Bipolar Disorder
Repligen Licenses Global Rights for Bipolar Disorder Treatment
SUN Pharmaceutical Industries to Divest Assets and Rights of Generic Drugs
AstraZeneca Signs Agreement with Abraxis BioScience
Roche Holding to Acquire Memory Pharmaceuticals
Scientists Find Common Genetic Profile between BPD and Schizophrenia
Wyeth Terminates Bifeprunox Accord with Solvay
Noven Pharmaceuticals Takes Over JDS Pharmaceuticals
9.FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories, Inc. (US)
AstraZeneca PLC (UK)
Bristol-Myers Squibb Company (US)
Cephalon, Inc. (USA)
Dainippon Sumitomo Pharma Co. Ltd. (Japan)
Eli Lilly and Company (US)
Forest Laboratories, Inc. (US)
Gedeon Richter PLC (Hungary)
GlaxoSmithKline PLC (UK)
H. Lundbeck A/S (Denmark)
Janssen Pharmaceutica, Inc. (US)
Parent Company Profile - Johnson and Johnson Company (US)
Merck & Co., Inc. (US)
Otsuka America Pharmaceutical Inc. (US)
Pfizer, Inc. (US)
Repligen Corporation (US)
Validus Pharmaceuticals, Inc. (US)
10.GLOBAL MARKET PERSPECTIVE
III. MARKET
1.THE UNITED STATES
A. MARKET ANALYSIS
Current and Future Analysis
Bipolar Disorder Facts
Major Trends
Mental Healthcare Expenditure Rising in the US
Antidepressants Grow as First-line Therapy for New Patients
Treatment for Bipolar Disorder Differs Based on Physician Specialty
American Children Prescribed More Psychotropic Drugs than European Children
Product Launches
Drug Approvals
Strategic Corporate Developments
Key Players
Abbott Laboratories, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Forest Laboratories, Inc.
Janssen Pharmaceutica, Inc.
Merck & Co., Inc.
Otsuka America Pharmaceutical, Inc.
Pfizer, Inc.
Repligen Corp.
Validus Pharmaceuticals, Inc.
B. MARKET ANALYTICS
2.EUROPE
A. MARKET ANALYSIS
Current and Future Analysis
Product Launch
Drug Approvals
B. MARKET ANALYTICS
2A.FRANCE
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
2B.GERMANY
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
2C.ITALY
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
2D.THE UNITED KINGDOM
A. MARKET ANALYSIS
Current and Future Analysis
Treatment Overview
List of Licensed Drugs for Bipolar Disorder Treatment
Lithium and Valproate Semisodium – Prescription Trends
Strategic Corporate Development
Key Players
AstraZeneca PLC
GlaxoSmithKline PLC
B. MARKET ANALYTICS
2E.SPAIN
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
2F.REST OF EUROPE
A. MARKET ANALYSIS
Current and Future Analysis
Key Players
Gedeon Richter PLC (Hungary)
H. Lundbeck A/S (Denmark)
B. MARKET ANALYTICS
3.ASIA-PACIFIC
A. MARKET ANALYSIS
Current and Future Analysis
Australia
Bipolar Disorder Facts
Product Approval
B. MARKET ANALYTICS
4.REST OF WORLD
A. MARKET ANALYSIS
Current and Future Analysis
Product Approval
Key Player
Dainippon Sumitomo Pharma Co. Ltd. (Japan)
B. MARKET ANALYTICS
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 53 (including Divisions/Subsidiaries - 64)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Atypical anti-psychotics
Other Therapeutics
II. EXECUTIVE SUMMARY
1.GLOBAL MARKET OVERVIEW
Bipolar Disorder Facts
A Market with Unmet Medical Needs
A Major Burden on Society
Current and Future Analysis
Patent Expiries Depress Market Growth
Patent Expiries of Major Bipolar Disorder Drugs
Loss of Exclusivity to Continue
Poor Pipeline Dims Prospects for Market Growth
A Few Bright Spots
Opportunities and Challenges
The Clinicians’ Quest for The Best - Seroquel XR
Children and Teens – The Targets or the Beneficiaries!
Adverse Events - A Major Issue with Antipsychotics
Side Effects Influence Prescription Trends
2.COMPETITIVE LANDSCAPE
A Market Sans Competition
Bipolar Disorder Drugs Market (2009): Five Major Companies with Marketed Products
Antipsychotics – The Mainstay Therapy
Table 1. Leading Players in Global Antipsychotic Drugs Market (2008): Annual Sales and Market Share Breakdown for Eli Lilly, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer (includes corresponding Graph/Chart)
Antidepressants
Table 2. Leading Drugs in the Global Antidepressants Market (2008): Revenues and Market Share Breakdown for Effexor, Cymbalta, Lexapro, Paxil/Wellbutrin, Zoloft and Remeron (includes corresponding Graph/Chart)
Antiepileptics – Prescriptions Continue Despite Warning
Select Antiepileptics with Approved Bipolar Disorder Indications
Table 3. Leading Players in the Global Antiepileptics Market (2008): Revenue in US$ Million and Market Share Breakdown for Pfizer, Johnson & Johnson, UCB Pharma, Abbott, GlaxoSmithKline and Others (includes corresponding Graph/Chart)
3.A REVIEW OF SELECT LEADING DRUGS
Abilify (Aripiprazole)
Geodon/Zeldox (Ziprasidone)
Invega (Paliperidone)
Lamictal (Lamotrigine)
Risperdal (Risperidone)
Risperdal® Consta® (Risperidone)
Saphris (Asenapine)
Seroquel (Quetiapine)
Seroquel XR
Zyprexa (Olanzapine)
Other Drugs
Depakine (Sodium Valproate)
Depakote/ Depakote ER (Divalproex Sodium)
Tegretol (Carbamazepine)
4.PIPELINE ANALYSIS
A Few Battle Big Challenges
Drug Development Pipeline for Select Bipolar Disorder Candidates
Bipolar Disorder Drugs (2009) –Select Companies with Products in Late Stage Clinical Development (Phase II, III, Pending Approvals)
A Review of Select Leading Pipeline Candidates
Lurasidone (SM-13,496)
Zomaril
Nuvigil (armodafinil)
RG2417 (Uridine)
RGH-188 (Cariprazine)
AZ - 004 (Staccato Loxapine)
Lu AA39959
Lu AA34893
5.DISEASE OVERVIEW
Introduction
History
Causes of Bipolar Disorder
Triggers
Episodes in a Bipolar Disorder
Classification of Bipolar Disorder
Bipolar Disorder Classification
Symptoms of Various Types of Bipolar Disorder
Mania
Hypomania
Mixed State
Depression
Additional Symptoms of Bipolar Episode
Treatment of Bipolar Disorder
Psychosocial Treatments
Hospitalization for Extreme Cases
6.CLINICAL TRIALS
Cephalon Announces Promising Phase II Clinical Results of NUVIGIL
Repligen Commences Phase IIB Trial of RG2417
Forest and Gedeon Richter Announce Favorable Phase II Results for Cariprazine
Alexza Commences Preliminary Phase 3 Trail with Staccato® Loxapine
Dainippon Sumitomo to Conduct Clinical Study for Lurasidone
7.PRODUCT APPROVALS AND LAUNCHES
AstraZeneca Introduces Seroquel XR® in North America
AstraZeneca Introduces Seroquel XR in Europe
Wockhardt to Roll Out Divalproex ER Tablets
FDA Approves SEROQUEL for Paediatric Treatment of Schizophrenia and Bipolar Disorder
FDA Approves Eli Lilly's Zyprexa for Schizophrenia and Bipolar Indications
Pfizer Canada Receives Approval from Health Canada for ZELDOX
Ortho-McNeil-Janssen Receives FDA Approval for RISPERDAL® CONSTA®
FDA Grants Approval to Eurand for EUR-1048
Merck/Schering-Plough Receives EMEA Approval for SYCREST®
FDA Approves SAPHRIS(R) for Treatment of Mixed/Manic Episodes of Bipolar Disorder and for Acute Treatment of Schizophrenia in Adults
FDA Grants Marketing Approval to Glenmark for Lithium Carbonate Capsules
Ranbaxy Australia Receives Approval from Therapeutic Goods Administration
Servier Obtains Approval for Valdoxan®/Thymanax®
Pfizer Canada Receives Approval from Health Canada for ZELDOX Drug
Pfizer Obtains Extended Approval for Geodon
FDA Considers Approval of Psychiatric Medications for Children
FDA Weighs Zyprexa for Two Juvenile Indications
Caraco Pharmaceutical Introduces Divalproex Sodium Delayed Release Tablets
BMS and Otsuka Obtain European Marketing Approval for ABILIFY® for Manic Episodes
ABILIFY® Obtains Extended Indications in Schizophrenia and Bipolar I Disorder
AstraZeneca Receives European MRP Approval for SEROQUEL and SEROQUEL XR
FDA Approves Seroquel XR® Extended Release Tablets
Mylan Pharmaceuticals Receives FDA Approval for Risperidone Tablets USP
Depakote Generic Drug Receives FDA Approval
Noven Pharmaceuticals Receives FDA Approval for Stavzor™
BMS and Otsuka Receive FDA Approval for ABILIFY®
Lupin Obtains FDA Approval for Divalproex Sodium Delayed-Release Tablets
Orchid Chemicals Obtains FDA Approval for Divalproex Sodium Delayed
Noven Pharmaceuticals Receives FDA Approval for Stavzor Capsules
Sun Pharmaceutical Industries Receives USFDA Approval for Depakote Divalproex Sodium Tablets
8.RECENT INDUSTRY ACTIVITY
Abbott Takes Over Solvay Pharmaceuticals
Merck & Co. Merges with Schering-Plough
Pfizer Acquires Wyeth
Hisamitsu Pharmaceutical and Hisamitsu U.S. Take Over Noven Pharmaceuticals
Avacta Group Acquires TheraGenetics
BMS and Otsuka Extend their Agreement on Ability
ADA Technologies to Develop Home Lithium-Monitor for Bipolar Disorder
Repligen Licenses Global Rights for Bipolar Disorder Treatment
SUN Pharmaceutical Industries to Divest Assets and Rights of Generic Drugs
AstraZeneca Signs Agreement with Abraxis BioScience
Roche Holding to Acquire Memory Pharmaceuticals
Scientists Find Common Genetic Profile between BPD and Schizophrenia
Wyeth Terminates Bifeprunox Accord with Solvay
Noven Pharmaceuticals Takes Over JDS Pharmaceuticals
9.FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories, Inc. (US)
AstraZeneca PLC (UK)
Bristol-Myers Squibb Company (US)
Cephalon, Inc. (USA)
Dainippon Sumitomo Pharma Co. Ltd. (Japan)
Eli Lilly and Company (US)
Table 4. Eli Lilly’s Leading Products (2009): Global Revenues in US$ Billion by Product – Zyprexa, Cymbalta, Humalog, Alimta, Cialis, Gemzar, Evista and Humulin (includes corresponding Graph/Chart)
Forest Laboratories, Inc. (US)
Gedeon Richter PLC (Hungary)
GlaxoSmithKline PLC (UK)
H. Lundbeck A/S (Denmark)
Janssen Pharmaceutica, Inc. (US)
Parent Company Profile - Johnson and Johnson Company (US)
Merck & Co., Inc. (US)
Otsuka America Pharmaceutical Inc. (US)
Pfizer, Inc. (US)
Repligen Corporation (US)
Validus Pharmaceuticals, Inc. (US)
10.GLOBAL MARKET PERSPECTIVE
Table 5. World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Geographic Region – US, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 6. World 10-Year Perspective for Bipolar Disorder Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
Table 7. World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Therapeutic Class – Atypical Anti-Psychotics, and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 8. World 10-Year Perspective for Bipolar Disorder Drugs by Therapeutic Class – Percentage Breakdown of Dollar Sales for Atypical Anti-Psychotics, and Other Therapeutics for Years 2006, 2009, and 2015
III. MARKET
1.THE UNITED STATES
A. MARKET ANALYSIS
Current and Future Analysis
Bipolar Disorder Facts
Major Trends
Mental Healthcare Expenditure Rising in the US
Antidepressants Grow as First-line Therapy for New Patients
Treatment for Bipolar Disorder Differs Based on Physician Specialty
American Children Prescribed More Psychotropic Drugs than European Children
Product Launches
Drug Approvals
Strategic Corporate Developments
Key Players
Abbott Laboratories, Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Table 9. Eli Lilly’s Leading Products (2009): Breakup of Global Revenues in US$ Billion by Product – Zyprexa, Cymbalta, Humalog, Alimta, Cialis, Gemzar, Evista and Humulin (includes corresponding Graph/Chart)
Forest Laboratories, Inc.
Janssen Pharmaceutica, Inc.
Merck & Co., Inc.
Otsuka America Pharmaceutical, Inc.
Pfizer, Inc.
Repligen Corp.
Validus Pharmaceuticals, Inc.
B. MARKET ANALYTICS
Table 10. US Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2.EUROPE
A. MARKET ANALYSIS
Current and Future Analysis
Product Launch
Drug Approvals
B. MARKET ANALYTICS
Table 11. European Recent Past, Current & Future Analysis for Bipolar Disorder Drugs by Geographic Region – France, Germany, Italy, the UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 12. European 10-Year Perspective for Bipolar Disorder Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, the UK, Spain, and Rest of Europe Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
2A.FRANCE
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
Table 13. French Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2B.GERMANY
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
Table 14. German Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2C.ITALY
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
Table 15. Italian Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2D.THE UNITED KINGDOM
A. MARKET ANALYSIS
Current and Future Analysis
Treatment Overview
List of Licensed Drugs for Bipolar Disorder Treatment
Lithium and Valproate Semisodium – Prescription Trends
Strategic Corporate Development
Key Players
AstraZeneca PLC
GlaxoSmithKline PLC
B. MARKET ANALYTICS
Table 16. The UK Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2E.SPAIN
A. MARKET ANALYSIS
Current and Future Analysis
B. MARKET ANALYTICS
Table 17. Spanish Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2F.REST OF EUROPE
A. MARKET ANALYSIS
Current and Future Analysis
Key Players
Gedeon Richter PLC (Hungary)
H. Lundbeck A/S (Denmark)
B. MARKET ANALYTICS
Table 18. Rest of Europe Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
3.ASIA-PACIFIC
A. MARKET ANALYSIS
Current and Future Analysis
Australia
Bipolar Disorder Facts
Product Approval
B. MARKET ANALYTICS
Table 19. Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
4.REST OF WORLD
A. MARKET ANALYSIS
Current and Future Analysis
Product Approval
Key Player
Dainippon Sumitomo Pharma Co. Ltd. (Japan)
B. MARKET ANALYTICS
Table 20. Rest of World Recent Past, Current & Future Analysis for Bipolar Disorder Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 53 (including Divisions/Subsidiaries - 64)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
